Clinical trials: Skin Sensitivity
Atopic Dermatitis, Eczema
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis
- Trial name
- NCT04021862
- Testing
- Bermekimab Monoclonal Antibody
- Where
- 17 sites in United States
- Volunteers
- 87 people
- Sponsor
- Janssen Research & Development, LLC
Asthma, Mastocytosis
Mast Cell Activation Test in Allergic Disease
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which…
- Conditions
- Asthma, Mastocytosis, Mast Cell Activation Syndrome, Food Allergy
- Trial name
- NCT03406325
- Where
- Hong Kong
- Volunteers
- 19 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Atopic Dermatitis
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis
- Trial name
- D2213C00001 (NCT02347176)
- Testing
- Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 204 people
- Sponsor
- MedImmune LLC
Allergic Contact Dermatitis
Bioequivalence of Ethylenediamine Dihydrochloride Study
The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.
- Trial name
- NCT01798589
- Testing
- Ethylenediamine dihydrochloride allergen patch
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Allerderm
Atopic Dermatitis
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis.
- Trial name
- NCT05142774
- Testing
- Tapinarof cream, 1%
- Where
- 112 sites in United States, Canada
- Volunteers
- 728 people
- Sponsor
- Organon and Co
Atopic Dermatitis
Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis
To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.
- Trial name
- NCT03018691
- Testing
- OPA-15406
- Where
- 4 sites in Japan
- Volunteers
- 73 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Atopic Dermatitis, Pruritus
Management of Pruritus With Xyzal in Atopic Dermatitis
It is historically well known that the management of pruritus in atopic dermatitis is very difficult. Most of the patients are not controlled with traditional antihistamines such as Clarinex, Claritin, and Allegra.
- Trial name
- NCT00884325
- Testing
- Levocetirizine dihydrochloride (Xyzal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Derm Research, PLLC
Atopic Dermatitis
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these…
- Trial name
- LEADS (NCT05436535)
- Testing
- Dupilumab, Vanicream- Dupilumab-naïve, Triamcinolone Acetonide
- Where
- 10 sites in United States
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
The coprimary objectives of the study are to: evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcineurin inhibitor (TCS/TCI), compared with placebo in combination with TCS/TCI at…
- Trial name
- ROCKET-SHUTTLE (NCT05724199)
- Testing
- Rocatinlimab
- Where
- 234 sites in United States, Argentina and 24 more
- Volunteers
- 746 people
- Sponsor
- Amgen
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
Photocil (Topical) for the Treatment of Atopic Dermatitis
Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B (NB-UVB) therapy when exposed to sunlight.
- Trial name
- NCT01992172
- Testing
- Photocil for Atopic Dermatitis
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Applied Biology, Inc.
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have…
- Trial name
- ECZTRA 7 (NCT03761537)
- Testing
- Tralokinumab
- Where
- 74 sites in Belgium, Czechia and 5 more
- Volunteers
- 277 people
- Sponsor
- LEO Pharma
Hereditary Angioedema (HAE)
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
- Trial name
- NCT02586805
- Testing
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Shire
Allergic Rhinitis, Asthma
Randomized Evaluation of Ten Allergy Skin Prick Test Devices
The goal of this study is to compare ten current and readily available FDA approved allergy skin prick devices to determine the most sensitive and specific product and methods used for the diagnosis of allergic disease.
- Conditions
- Allergic Rhinitis, Asthma, Food Allergy, Skin Testing
- Trial name
- NCT03509766
- Testing
- Histamine skin testing
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Atopic Dermatitis, Eczema
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADhope (NCT05990725)
- Testing
- Lebrikizumab
- Where
- 33 sites in Germany, Netherlands and 1 more
- Volunteers
- 260 people
- Sponsor
- Almirall, S.A.
Hereditary Angioedema (HAE)
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE participants.
- Trial name
- NCT02093923
- Testing
- DX-2930
- Where
- 14 sites in United States, Italy and 1 more
- Volunteers
- 38 people
- Sponsor
- Shire
Dermatitis, Atopic
A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT04365387
- Testing
- Nemolizumab
- Where
- 64 sites in United States
- Volunteers
- 242 people
- Sponsor
- Galderma R&D
Chronic Urticaria
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.
- Trial name
- NCT00481676
- Testing
- Omalizumab 75-375 mg, Loratadine, Clemastine
- Where
- 11 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Novartis
Hereditary Angioedema
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities…
- Trial name
- NCT00292981
- Testing
- C1 Esterase Inhibitor
- Where
- 14 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- CSL Behring